{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:59:29Z","timestamp":1778878769248,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,3,18]],"date-time":"2011-03-18T00:00:00Z","timestamp":1300406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00280-011-1614-z","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T05:53:43Z","timestamp":1300341223000},"page":"1223-1231","source":"Crossref","is-referenced-by-count":25,"title":["Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis"],"prefix":"10.1007","volume":"68","author":[{"given":"Claudia","family":"Lebedinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn C.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Soto-Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trilok","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Lardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,18]]},"reference":[{"issue":"Suppl 7","key":"1614_CR1","doi-asserted-by":"crossref","first-page":"vii173","DOI":"10.1093\/annonc\/mdq295","volume":"21","author":"I Brana","year":"2010","unstructured":"Brana I, Tabernero J (2010) Cardiotoxicity. Ann Oncol 21(Suppl 7):vii173\u2013vii179","journal-title":"Ann Oncol"},{"key":"1614_CR2","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","volume":"23","author":"JD Floyd","year":"2005","unstructured":"Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685\u20137696","journal-title":"J Clin Oncol"},{"key":"1614_CR3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185\u2013229","journal-title":"Pharmacol Rev"},{"key":"1614_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1470-2045(09)70042-7","volume":"10","author":"R Altena","year":"2009","unstructured":"Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 10:391\u2013399","journal-title":"Lancet Oncol"},{"key":"1614_CR5","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231\u20132247","journal-title":"J Am Coll Cardiol"},{"key":"1614_CR6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pcad.2010.05.006","volume":"53","author":"G Curigliano","year":"2010","unstructured":"Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A (2010) Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 53:94\u2013104","journal-title":"Prog Cardiovasc Dis"},{"key":"1614_CR7","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/bi960306b","volume":"35","author":"Y Pommier","year":"1996","unstructured":"Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303\u201313309","journal-title":"Biochemistry"},{"key":"1614_CR8","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1158\/1535-7163.MCT-04-0316","volume":"4","author":"N Martinez","year":"2005","unstructured":"Martinez N, Sanchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernandez I, Navarrete M, Jimeno J, Piris MA (2005) Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 4:814\u2013823","journal-title":"Mol Cancer Ther"},{"key":"1614_CR9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","volume":"37","author":"E Erba","year":"2001","unstructured":"Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D\u2019Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37:97\u2013105","journal-title":"Eur J Cancer"},{"key":"1614_CR10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1074-5521(01)00082-5","volume":"8","author":"EJ Martinez","year":"2001","unstructured":"Martinez EJ, Corey EJ, Owa T (2001) Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 8:1151\u20131160","journal-title":"Chem Biol"},{"key":"1614_CR11","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2165\/00003495-200767150-00009","volume":"67","author":"NJ Carter","year":"2007","unstructured":"Carter NJ, Keam SJ (2007) Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67:2257\u20132276","journal-title":"Drugs"},{"key":"1614_CR12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.1221","volume":"92","author":"G Damia","year":"2001","unstructured":"Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D\u2019Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92:583\u2013588","journal-title":"Int J Cancer"},{"key":"1614_CR13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","volume":"7","author":"Y Takebayashi","year":"2001","unstructured":"Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961\u2013966","journal-title":"Nat Med"},{"key":"1614_CR14","first-page":"4899","volume":"62","author":"T Furuta","year":"2002","unstructured":"Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899\u20134902","journal-title":"Cancer Res"},{"key":"1614_CR15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-07-2432","volume":"7","author":"JA Casado","year":"2008","unstructured":"Casado JA, Rio P, Marco E, Garcia-Hernandez V, Domingo A, Perez L, Tercero JC, Vaquero JJ, Albella B, Gago F, Bueren JA (2008) Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 7:1309\u20131318","journal-title":"Mol Cancer Ther"},{"key":"1614_CR16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2165\/00003495-200262080-00005","volume":"62","author":"RS Cvitkovic","year":"2002","unstructured":"Cvitkovic RS, Figgitt DP, Plosker GL (2002) Et-743. Drugs 62:1185\u20131192 (discussion 1193\u20131184)","journal-title":"Drugs"},{"key":"1614_CR17","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1358\/dof.1996.021.11.385487","volume":"21","author":"J Jimeno","year":"1996","unstructured":"Jimeno J, Faircloth G, Cameron L, Meely K, Vega E, G\u00f3mez A (1996) Progress in the acquisition of new marine-derived anticancer compounds: development of Ecteinascidin-743 (ET-743). Drugs Future 21:1155\u20131165","journal-title":"Drugs Future"},{"key":"1614_CR18","first-page":"1631","volume":"2","author":"CF Verschraegen","year":"2001","unstructured":"Verschraegen CF, Glover K (2001) ET-743 (PharmaMar\/NCI\/Ortho Biotech). Curr Opin Investig Drugs 2:1631\u20131638","journal-title":"Curr Opin Investig Drugs"},{"key":"1614_CR19","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1517\/13543784.12.11.1843","volume":"12","author":"M D\u2019Incalci","year":"2003","unstructured":"D\u2019Incalci M, Jimeno J (2003) Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 12:1843\u20131853","journal-title":"Expert Opin Investig Drugs"},{"key":"1614_CR20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","volume":"22","author":"R Garcia-Carbonero","year":"2004","unstructured":"Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD (2004) Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22:1480\u20131490","journal-title":"J Clin Oncol"},{"key":"1614_CR21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","volume":"22","author":"A Yovine","year":"2004","unstructured":"Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22:890\u2013899","journal-title":"J Clin Oncol"},{"key":"1614_CR22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","volume":"23","author":"A Le Cesne","year":"2005","unstructured":"Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23:576\u2013584","journal-title":"J Clin Oncol"},{"key":"1614_CR23","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1200\/JCO.2005.09.032","volume":"23","author":"C Sessa","year":"2005","unstructured":"Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D\u2019Incalci M, Dall\u2019o E, Colombo N (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867\u20131874","journal-title":"J Clin Oncol"},{"key":"1614_CR24","unstructured":"Monk BJ, Herzog T, Kaye S, Krasner CN, Vermorken J, Muggia F, Pujade-Lourraine E, Renshaw FG, Lebedinsky C, Poveda A (2008) A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann Oncol 19:viii1\u2013viii4, LBA4; doi: 10.1093\/annonc\/mdn1649"},{"key":"1614_CR25","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdp198","volume":"20","author":"JM Del Campo","year":"2009","unstructured":"Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C (2009) Phase II randomized study of trabectedin given as two different every 3\u00a0weeks dose schedules (1.5\u00a0mg\/m2 24\u00a0h or 1.3\u00a0mg\/m2 3\u00a0h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 20:1794\u20131802","journal-title":"Ann Oncol"},{"key":"1614_CR26","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.bjc.6604088","volume":"97","author":"CN Krasner","year":"2007","unstructured":"Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME (2007) A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97:1618\u20131624","journal-title":"Br J Cancer"},{"key":"1614_CR27","doi-asserted-by":"crossref","unstructured":"Michaelson MD, Gilligan T, Oh W, Kantoff P, Taplin M, Izquierdo MA, Flores L, Smith MR (2005) Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol ASCO Ann Meet Proc 23:4517","DOI":"10.1200\/jco.2005.23.16_suppl.4517"},{"key":"1614_CR28","doi-asserted-by":"crossref","unstructured":"Gurtler JS, Goldstein L, Delprete S, Tjulandin S, Semiglazov V, Sternas L, Michiels B, Gilles E (2005) Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol ASCO Ann Meet Proc 23:625","DOI":"10.1200\/jco.2005.23.16_suppl.625"},{"key":"1614_CR29","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.bjc.6603142","volume":"94","author":"L Zelek","year":"2006","unstructured":"Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Misset JL (2006) A phase II study of Yondelis((R)) (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 94:1610\u20131614","journal-title":"Br J Cancer"},{"key":"1614_CR30","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188\u20134196","journal-title":"J Clin Oncol"},{"key":"1614_CR31","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM (2010) Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107\u20133114","journal-title":"J Clin Oncol"},{"key":"1614_CR32","doi-asserted-by":"crossref","unstructured":"Cioffi A, LeCesne A, Blay J-Y, Delaloge S, Yovine A, Maki R, Nieto A, Jiao JJ, Demetri GD (2009) Trabectedin phase II clinical trials: pooled analysis of safety in patients with solid tumors. J Clin Oncol 27:abstr e13510","DOI":"10.1200\/jco.2009.27.15_suppl.e13510"},{"key":"1614_CR33","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","volume":"25","author":"JR Carver","year":"2007","unstructured":"Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ (2007) American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25:3991\u20134008","journal-title":"J Clin Oncol"},{"key":"1614_CR34","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900\u20132902","journal-title":"J Clin Oncol"},{"key":"1614_CR35","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215\u20131221","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1614_CR36","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s12325-009-0048-z","volume":"26","author":"M Fiuza","year":"2009","unstructured":"Fiuza M (2009) Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Ther 26(Suppl 1):S9\u2013S17","journal-title":"Adv Ther"},{"key":"1614_CR37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","volume":"104","author":"DJ Lenihan","year":"2004","unstructured":"Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M (2004) Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome. Blood 104:655\u2013658","journal-title":"Blood"},{"key":"1614_CR38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157488610789869111","volume":"5","author":"C Bagnes","year":"2010","unstructured":"Bagnes C, Panchuk PN, Recondo G (2010) Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf 5:93\u201396","journal-title":"Curr Drug Saf"},{"key":"1614_CR39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1634\/theoncologist.7-1-65","volume":"7","author":"DL Keefe","year":"2002","unstructured":"Keefe DL (2002) The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist 7:65\u201372","journal-title":"Oncologist"},{"key":"1614_CR40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00520-007-0397-6","volume":"16","author":"R Jurcut","year":"2008","unstructured":"Jurcut R, Wildiers H, Ganame J, D\u2019Hooge J, Paridaens R, Voigt JU (2008) Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer 16:437\u2013445","journal-title":"Support Care Cancer"},{"key":"1614_CR41","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-94-4-430","volume":"94","author":"JS Gottdiener","year":"1981","unstructured":"Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH, Schwartz DE, Bacharach SL, Green MV, Rosenberg SA (1981) Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94:430\u2013435","journal-title":"Ann Intern Med"},{"key":"1614_CR42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337","journal-title":"BMC Cancer"},{"key":"1614_CR43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/187152508785909474","volume":"6","author":"AL Ferreira","year":"2008","unstructured":"Ferreira AL, Matsubara LS, Matsubara BB (2008) Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 6:278\u2013281","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"1614_CR44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419\u2013436","journal-title":"Clin Pharmacokinet"},{"key":"1614_CR45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","volume":"19","author":"AA Gabizon","year":"2001","unstructured":"Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424\u2013436","journal-title":"Cancer Invest"},{"key":"1614_CR46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cpcardiol.2008.01.002","volume":"33","author":"SW Yusuf","year":"2008","unstructured":"Yusuf SW, Razeghi P, Yeh ET (2008) The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol 33:163\u2013196","journal-title":"Curr Probl Cardiol"},{"key":"1614_CR47","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","volume":"25","author":"EL Strevel","year":"2007","unstructured":"Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362\u20133371","journal-title":"J Clin Oncol"},{"key":"1614_CR48","unstructured":"Manikhas GM, Dirix L, Vermorken JB, Park K, Jain M, Thertulien R, Gonzalez M, Jiao J, Parekh TV, Staddon AP (2010) A single-blind, placebocontrolled, sequential design study evaluating the potential effects of trabectedin on the QT intervals. J Clin Oncol 28:Abstract e13096"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1614-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1614-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1614-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T11:57:50Z","timestamp":1637409470000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1614-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,18]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1614-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,18]]}}}